Optimizing Care Models for Bispecific Antibodies: Strategies for Cost-Effective Delivery

Jeffrey V. Matous, MD, discusses how best practices in transitioning care between academic and community centers can enhance patient outcomes when receiving bispecific antibodies, and the critical role managed care organizations play in facilitating cost-effective integration of these therapies into community settings through optimized partnerships.

EP: 1.Emerging Bispecifics in Multiple Myeloma: Real-World Insights and Treatment Strategies

EP: 2.Navigating Adverse Events in Bispecific Antibody Therapies: Infection Prevention and Management

EP: 3.Proactive CRS Management: The Role of Tocilizumab and Beyond

EP: 4.Expanding Bispecific Therapies to Community Settings: Challenges and Innovations

EP: 5.Leveraging Telehealth and Collaboration for Rural and Community Care Expansion

EP: 6.Streamlining Transitions Between Academic and Community Centers

Now Viewing

EP: 7.Optimizing Care Models for Bispecific Antibodies: Strategies for Cost-Effective Delivery

Video content above is prompted by the following:

• What best practices can improve transitions of care between academic and community centers for patients receiving bispecific antibodies?
• What role do managed care organizations play in facilitating the integration of bispecific antibody therapies into community settings, and how can partnerships be optimized to ensure cost-effective care delivery?

Related Videos